What is a HER2-positive in breast cancer in 2018?

被引：0
|
作者：
Schnitt, S. [1 ]
机构：
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-ES1-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ES1-1
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [42] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Danijela Jelovac
    Antonio C. Wolff
    Current Treatment Options in Oncology, 2012, 13 : 230 - 239
  • [43] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [44] Her2-positive breast cancer: Herceptin and beyond
    Dean-Colomb, Windy
    Esteva, Francisco J.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2806 - 2812
  • [45] Progression and treatment of HER2-positive breast cancer
    Davoli, April
    Hocevar, Barbara A.
    Brown, Thomas L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 611 - 623
  • [46] Neratinib (Nerlynx) for HER2-Positive Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1539): : 23 - 23
  • [47] Mutational characterization of HER2-positive breast cancer
    Velasco Sanchez, A.
    Gasol Cudos, A.
    Morales, S.
    Veas Rodriguez, J.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [49] Personalized Medicine in HER2-positive breast cancer
    Tsurutani, Junji
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Advances in targeting HER2-positive breast cancer
    Harbeck, Nadia
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 55 - 59
12345